China Biologic Products Inc. (NASDAQ:CBPO) dropped 1.6% during trading on Friday . The stock traded as low as $110.58 and last traded at $111.05, with a volume of 81,299 shares changing hands. The stock had previously closed at $112.88.

CBPO has been the subject of several recent research reports. Jefferies Group restated a “buy” rating on shares of China Biologic Products in a report on Saturday, June 4th. Zacks Investment Research downgraded China Biologic Products from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Finally, Credit Suisse Group AG upgraded China Biologic Products from a “neutral” rating to an “outperform” rating in a report on Tuesday, July 5th.

The company has a market cap of $2.97 billion and a P/E ratio of 33.42. The stock’s 50-day moving average is $111.47 and its 200 day moving average is $117.17.

China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.06. The company had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $74 million. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. Equities analysts forecast that China Biologic Products Inc. will post $4.29 EPS for the current year.

In related news, CFO Ming Yang sold 13,908 shares of China Biologic Products stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $113.64, for a total transaction of $1,580,505.12. Following the transaction, the chief financial officer now owns 52,282 shares of the company’s stock, valued at $5,941,326.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Wp X. Biologics Llc sold 2,775,000 shares of China Biologic Products stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $111.00, for a total value of $308,025,000.00. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently made changes to their positions in the stock. Employees Retirement System of Texas bought a new position in shares of China Biologic Products during the fourth quarter valued at about $2,846,000. WCM Investment Management CA boosted its position in shares of China Biologic Products by 22.8% in the fourth quarter. WCM Investment Management CA now owns 60,753 shares of the biopharmaceutical company’s stock valued at $8,655,000 after buying an additional 11,282 shares during the last quarter. ProShare Advisors LLC bought a new position in shares of China Biologic Products during the fourth quarter valued at about $3,040,000. Finally, Russell Frank Co boosted its position in shares of China Biologic Products by 69.1% in the fourth quarter. Russell Frank Co now owns 14,104 shares of the biopharmaceutical company’s stock valued at $1,993,000 after buying an additional 5,764 shares during the last quarter.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.